Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment Syndivia SAS, headquartered in Illkirch, France, is a biotechnology company developing best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates (ADC).
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/syndivia” connections=”true” suffix=””]
Syndivias APN technology (Plasma-stable cysteine conjugation) enable the preparation of ADCs having increased stability in blood circulation thus widens the therapeutic index of the conjugates in oncology applications. Its C&R technology allows for tumor-specific release of the cytotoxic payload both inside cancer cells and in tumor microenvironment and DARX technology allows scalable industrial process for stochiometric chemical protein fusion.
In Sep 2016, Syndivia and OGD2 Pharma SAS collaborate to develop an Antibody-Drug Conjugate targeting the O-acetyl-GD2 cancer antigen. New drugs to use Syndivias stable payloads for intracellular and tumor microenvironment specific drug release and OGD2 Pharmas innovative immunotherapy agents targeting OAcGD2 antigen. The financial details remains undisclosed.
In Aug 2016, Syndivia received a grant worth 50K from European Commission, European Innovation as one of the new Phase 1 beneficiaries of the European Unions SME Instrument.